Xeris Biopharma Holdings, Inc. XERS Accrued trade discounts and rebates
Accrued trade discounts and rebates at other companies
Other financials
Where this comes from
Reported directly by Xeris Biopharma Holdings, Inc. in its filing.
Tagged under the XBRL concept xers:AccrualForRebatesAndTradeDiscounts.
The official record: Xeris Biopharma Holdings, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Xeris Biopharma Holdings, Inc.'s accrued trade discounts and rebates.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xeris Biopharma Holdings, Inc.'s accrued trade discounts and rebates?
- Xeris Biopharma Holdings, Inc. (XERS) reported accrued trade discounts and rebates of $45.49M in Q1 2026.
- How has Xeris Biopharma Holdings, Inc.'s accrued trade discounts and rebates changed year-over-year?
- Xeris Biopharma Holdings, Inc.'s accrued trade discounts and rebates increased by 48.0% year-over-year, from $30.73M to $45.49M.
- What is the long-term trend for Xeris Biopharma Holdings, Inc.'s accrued trade discounts and rebates?
- Over 5 years (2020 to 2025), Xeris Biopharma Holdings, Inc.'s accrued trade discounts and rebates has grown at a 48.5% compound annual growth rate (CAGR), from $5.98M to $43.25M.
- What does accrued trade discounts and rebates mean?
- This represents the estimated liability for contractual rebates, volume discounts, and prompt payment incentives owed to wholesalers, distributors, or pharmacy benefit managers. It reflects the company's obligation to provide price concessions on products already sold to the distribution channel. Monitoring this balance helps investors assess the impact of pricing strategies and the potential for future revenue adjustments.